Keynote R・A vol.3no.1(2015 1) ASCO 2021: Results from the KEYNOTE-564 Study of Adjuvantの詳細情報
ASCO 2021: Results from the KEYNOTE-564 Study of Adjuvant。USGS Open-File Report 2008-1115: Geologic Field Notes。ASCO GU 2019: Phase III KEYNOTE-426 Study: Pembrolizumab。